Background. Virginiamycin use in poultry selects for Enterococcus faecium with cross-resistance to quinupristindalfopristin, a drug for vancomycin-resistant E. faecium in humans. We conducted an epidemiologic study of poultry exposures as risk factors for human carriage of quinupristin-dalfopristin-resistant E. faecium.
antimicrobial quinupristin-dalfopristin is 1 of 3 drugs licensed by the US Food and Drug Administration (FDA) for the treatment of serious vancomycin-resistant E. faecium infections in the United States. A related streptogramin antibiotic, virginiamycin, has been used as a growth promoter in US livestock since 1975. Virginiamycin is administered to poultry in feed to increase weight gain [3] . The drug is also used as a growth promoter in swine. Several studies have demonstrated a relationship between the prevalence of quinupristindalfopristin-resistant E. faecium in food animals and the magnitude of virginiamycin use as a growth promoter [4] [5] [6] . Denmark banned virginiamycin use as a growth promoter in 1997, and the European Union subsequently banned virginiamycin and 3 other antimicrobial growth promoters [7] .
Quinupristin-dalfopristin is a mixture of 2 streptogramin compounds (A and B) that inhibit bacterial protein synthesis through different mechanisms. Clinical quinupristin-dalfopristin resistance was reported in a small number of patients during prelicensure studies [8] . In E. faecium, streptogramin A resistance is encoded by the acetyltransferase genes vatD and vatE, which are located on plasmids [9] [10] [11] . Streptogramin B resistance is mediated by erythromycin resistance methylase (ermB) genes [12, 13] . These genes do not account for all quinupristin-dalfopristin-resistant E. faecium, and other mechanisms of resistance remain undefined [14] [15] [16] .
Microbiological studies have demonstrated that quinupristin-dalfopristin-resistant E. faecium are prevalent on poultry farms and in retail poultry in the United States [16] [17] [18] [19] . Other studies have shown that feeding virginiamycin to chickens and turkeys leads to the emergence of quinupristin-dalfopristinresistant E. faecium [20] [21] [22] . However, the testing of selected human fecal samples has suggested that human colonization with quinupristin-dalfopristin-resistant E. faecium is rare in the United States [19] . The latter observation was a key factor in a proposed FDA risk-assessment model regarding streptogramin use in animals and human infections with quinupristin-dalfopristin-resistant E. faecium. We conducted an epidemiologic study of quinupristin-dalfopristin susceptibility in E. faecium colonizing humans and retail poultry and assessed the association between poultry exposure and the isolation of quinupristin-dalfopristin-resistant E. faecium from the gastrointestinal tract of humans.
PATIENTS, MATERIALS, AND METHODS
Study design and population. This was a cross-sectional survey of quinupristin-dalfopristin-resistant E. faecium in recently admitted hospital patients, healthy vegetarians, and retail poultry in 4 communities. The enrollment community hospitals included St. Joseph's Hospital, Marshfield, Wisconsin; Gundersen Lutheran Hospital, La Crosse, Wisconsin; Sacred Heart Hospital, Eau Claire, Wisconsin; and Rice Memorial Hospital, Willmar, Minnesota.
Participant recruitment. Newly admitted hospital patients were enrolled from June 2002 through May 2003. Subjects were enrolled to yield ∼150 participants per hospital, distributed evenly throughout the 12-month period. Patients у14 years old admitted to a medical, surgical, or intensive care unit (ICU) bed were eligible if they were alert, stable, and capable of giving informed consent. Patients with acute rectal bleeding, recent use of cathartics, or neutropenia were excluded. Rectal-swab samples were obtained within 36 h of hospital admission for all patients.
Vegetarian participants were recruited from January through July 2004 at health-food cooperatives located in or near the 4 study communities. Adult vegetarians were eligible to participate if they reported no consumption of meat products for at least 1 year. Stool samples were obtained from vegetarian participants for the isolation and characterization of E. faecium.
Hospital patients and vegetarians were interviewed by telephone regarding potential dietary and environmental sources of E. faecium. Interviews were conducted within 62 days of enrollment for hospital patients and at the time of enrollment for vegetarians. The main exposures of interest included touching raw meat, consuming meat products, and contact with live food animals. For hospital patients, information on recent antibiotic use and chronic diseases was obtained through abstraction of medical records. The study protocol was approved by the Marshfield Clinic's institutional review board, and all participants provided written, informed consent.
Retail poultry samples. Retail poultry samples were collected 4 times during the 12-month hospital recruitment period from grocery stores in the 4 study communities. During each visit to a community, we purchased a convenience sample of ∼8 chicken and 2 turkey products from various retail locations.
These retail samples, designated "conventional retail poultry," were selected without regard to label information concerning antibiotic use on the farm. During an additional collection period, retail poultry products were purchased from food cooperatives and natural-food stores in or near the study communities. These poultry products, designated "antibiotic-free retail poultry," were confirmed to be raised without antibiotics on the basis of the product label or by contacting the manufacturer or distributor.
Laboratory methods. Stool samples and rectal swabs were suspended in brain-heart infusion (BHI) broth overnight at 37ЊC. Retail poultry samples were massaged in buffered peptone water, and the rinsate was centrifuged at 3070 g to yield 1 mL of concentrate for inoculation into BHI. E. faecium was isolated on colistin-naladixic acid agar, identified using standard biochemical procedures, and confirmed by polymerase chain reaction (PCR) for a species-specific ddl amplicon [23] . A total of 5-6 randomly selected isolates from each sample were evaluated for resistance to quinupristin-dalfopristin. Quinupristindalfopristin susceptibility was measured by E-test using a recognized reference standard for the interpretation of MICs [24] . Isolates with MICs у4 mg/mL were classified as resistant, and those with MICs between 1 and 4 mg/mL were classified as having intermediate resistance.
An E. faecium isolate representing each level of quinupristindalfopristin resistance (susceptible, intermediate, or resistant) found in each sample (5-6 isolates) was selected for further evaluation. Ten genetic markers were evaluated initially in the hospital patients : vatA, vatB, vatC, vgaA, vgaB, vgbA, vgbB, vatE, vatD , and ermB [13-16, 25, 26] . Only the latter 3 were identified, and subsequent PCR testing for genetic markers was limited to this group. Positive results were confirmed by DNA sequencing. Representative isolates from humans and retail poultry were char- acterized using pulsed-field gel electrophoresis (PFGE) at the Minnesota Department of Health (St. Paul) [27] . E. faecium isolates that were sensitive or had intermediate resistance to quinupristin-dalfopristin (MICs !4 mg/mL) were tested for the detection of inducible resistance [28] . Initially, E. faecium (measured by optical density) in the log 6 5 ϫ 10 phase of growth were transferred to 5 mL of BHI broth that contained 0.25 mg/mL virginiamycin and cultured at 37ЊC for 24 h. The bacterial density was readjusted to /mL in 6 1 ϫ 10 fresh BHI broth, challenged with 8 mg/mL quinupristin-dalfopristin, and incubated for another 24 h at 37ЊC. The level of inducible quinupristin-dalfopristin resistance was expressed as relative growth, defined as the 24-h optical density (at 600 nm) of the isolate preexposed to virginiamycin and challenged with quinupristin-dalfopristin divided by the optical density of the same isolate cultured in BHI broth for 24 h without virginiamycin before exposure or quinupristin-dalfopristin challenge. This ratio was multiplied by 100 to yield the relative percentage of growth, with possible values ranging from 0% (no inducible resistance) to 100% (high level of inducible resistance). The inducibility assay was also performed for isolates from hospital patients after preexposure to 0.25 mg/mL of quinupristin-dalfopristin instead of virginiamycin.
Statistical analysis. Statistical analyses were based on the E. faecium isolate with the highest level of constitutive quinupristin-dalfopristin resistance in each sample. The primary outcomes included the presence of the vatE gene and the level of inducible resistance, measured as the relative percentage of growth. Contact with raw poultry and frequency of poultry consumption were the primary exposures of interest. The latter was dichotomized at the median consumption level for hospital patients. Vegetarians made up a separate category of poultry consumption.
Unadjusted associations between the exposure and outcome measures were assessed using Fisher's exact test, the Wilcoxon rank-sum test, or the Kruskal-Wallis test. Multivariable regression models were used to estimate adjusted measures of association. Separate models were constructed for each combination of population (hospital patients alone or the combined group of hospital patients and vegetarians), outcome, and exposure. Variables were screened for inclusion in an initial multivariable model. Candidate variables with were re-P р 0.20 tained. Collinearity was assessed in the resulting model [29, 30] . Final models included variables that achieved statistical significance ( ) or whose exclusion altered the outcome-P р 0.05 exposure measure of association by 110%.
For the vatE models, adjusted prevalence ratios were computed using methods described by Zou [31] . Linear regression was used for the inducible resistance models. Because the distribution of inducible resistance was skewed, the natural log transformation was applied before models were fitted. Applying the inverse transformation to the fitted linear model resulted in a model of the median response on the original scale [32] . The measure of association for the inducible resistance models was the median relative percentage of growth in the exposed group divided by that in the unexposed group. For both measures of association (prevalence ratios for vatE and ratios of medians for inducible resistance), a value of 1.0 indicated no effect, and values 11.0 indicated an association between the exposure and outcome of interest. All analyses were performed using SAS software (version 9.1; SAS Institute).
The following variables were screened for inclusion in the multivariable models: touching raw poultry; touching raw beef; touching raw pork; frequency of consumption of poultry, beef, and pork; cooking one's own meals; age; sex; education; employment status; state of residence; alcohol consumption; and physician visits, hospitalizations, and ICU admissions during the prior year. Vegetarian status was screened for inclusion in the models when relevant. For analyses of hospital patients alone, hospital location and a comorbidity index [33] were also assessed for inclusion in the models.
RESULTS
There were 1614 eligible patients contacted within 36 h after hospital admission, and 622 (39%) agreed to participate. Of these, 55 were excluded from the analysis because of specimen shipping delays ( ) or because the risk-factor interview n p 12 was not completed ( ). For the remaining 567 patients, n p 43 the median interval from hospital admission to fecal specimen collection was 25 h (range, 11-36 h). The median time between enrollment and completion of the risk-factor interview was 22 days (range, 5-62 days). One hundred vegetarians provided stool samples and completed the risk-factor interview. E. faecium was isolated from 105 hospital patients and 65 vegetarians; further analyses were restricted to this group. Compared with vegetarians, the hospital patients were more likely to be older and male, with less formal education (table 1) .
None of the human E. faecium isolates had constitutive resistance to quinupristin-dalfopristin (MIC у4 mg/mL) by Etest, but a majority of isolates from both hospital patients and vegetarians had intermediate quinupristin-dalfopristin resistance (table 2) . Neither vatE nor ermB was found in vegetarian E. faecium isolates; vatE was commonly found in isolates from the hospital patients. ErmB was present in !10% of hospital patient isolates, and vatD was found in 1 E. faecium isolate from a hospital patient. The rarity of ermB and vatD genes in the study population prevented the effective evaluation of their role in the association between poultry exposure and quinupristin-dalfopristin resistance.
E. faecium was isolated from 77 (48%) of 160 conventional retail poultry samples and 23 (88%) of 26 antibiotic-free retail poultry samples. Quinupristin-dalfopristin resistance was more common in isolates from conventional than antibiotic-free retail poultry (table 2) . Conventional retail poultry isolates were ∼4 times more likely to contain vatE ( ) and ermB P p .004 ( ) than were isolates from antibiotic-free retail poultry. P p .005 All PFGE patterns from humans and retail poultry were distinct, and no common clones were identified in both sources (data not shown).
The level of inducible resistance to quinupristin-dalfopristin (expressed as relative percentage of growth) varied greatly in E. faecium isolates from different sources (figure 1). Higher inducible resistance levels were found in E. faecium isolates from hospital patients than in those from vegetarians. The median relative percentage of growth was 6.5% (range, 1.3%-56.4%) for isolates from hospital patients and 2.4% (range, 1.2%-4.6%) for isolates from vegetarians ( ). For isolates from hos-P ! .001 pital patients that were preexposed to quinupristin-dalfopristin, the median relative percentage of growth was 6.1% (range, 0.8%-45.8%). Without preexposure to virginiamycin or quinupristin-dalfopristin, isolates from hospital patients did not grow when challenged with 8 mg/mL quinupristin-dalfopristin (median relative percentage of growth, 2.0%; range, 0.9%-8.2%). When measured by E-test, 25 (24%) of 105 isolates from hospital patients became resistant to quinupristin-dalfopristin (MIC у4 mg/mL) after preexposure to virginiamycin; the median MIC of these resistant isolates after induction was 8 mg/ mL (range, 4-32 mg/mL). The relative percentage of growth after preexposure to virginiamycin and quinupristin-dalfopristin challenge was correlated with the MIC measurement of resistance after induction (Spearman's correlation, 0.55 [95% confidence interval {CI}, 0.40-0.67]).
Inducible quinupristin-dalfopristin resistance was associated with the presence of vatE. The median relative percentage of Figure 1 . Plots of inducible resistance for Enterococcus faecium isolated from humans and retail poultry with initial E-test MICs !4 mg/mL for quinupristin-dalfopristin. Each symbol represents 1 isolate. Inducible resistance (relative percentage of growth) was determined by dividing the 24-h growth density of isolates after preexposure to virginiamycin and quinupristin-dalfopristin challenge by the 24-h growth density of untreated isolates and multiplying by 100.
growth after preexposure to virginiamycin was 15.8% (interquartile range [IQR], 9.0%-26.2%) for isolates that contained vatE and 2.6% (IQR, 2.0%-3.7%) for those without vatE ( ). The PFGE patterns of the inducible isolates were P ! .001 distinct from each other. For each isolate, the pattern after induction and quinupristin-dalfopristin challenge was indistinguishable from the original pattern before induction, which is consistent with inducible resistance rather than selection of a contaminating isolate with constitutive resistance.
E. faecium isolates from conventional retail poultry had higher levels of inducible resistance than isolates from antibiotic-free retail poultry. The median relative percentage of growth was 30.6% (range, 1.4%-47.8%) for conventional retail poultry isolates and 2.2% (range, 1.5%-6.6%) for antibioticfree retail poultry isolates ( ). P ! .001 Risk-factor analysis. The association between poultry exposures and carriage of E. faecium with vatE differed among hospital patients with and without prior antibiotic use. Fortyfive (43%) of 105 hospital patients with E. faecium had used antibiotics during the month before enrollment. The most common antibiotics used were b-lactams (70%), fluoroquinolones (29%), and macrolides (9%). Among these patients, touching raw poultry did not increase the risk of carrying E. faecium with vatE (prevalence ratio, 0.55 [95% CI, 0.31-0.96]). By contrast, the hospital patients without recent antibiotic use had a increased risk of carrying E. faecium isolates with vatE if they had touched raw poultry (prevalence ratio, 1.94 [95% CI, 0.73-5.15];
for both exposures, Breslow-Day test) [34] . None P р .05 of the vegetarians with E. faecium had used antibiotics during the month before enrollment. On the basis of these findings, results are reported for participants without recent antibiotic use.
Carriage of E. faecium with vatE was significantly associated with both touching raw poultry and higher poultry consumption in the combined hospital patient and vegetarian group (table 3) . Inducible resistance was significantly associated with higher poultry consumption in this group. In the multivariable models, we found higher point estimates for both raw poultry contact and poultry consumption in persons without recent antibiotic use, but not all of these were statistically significant (table 4). Carriage of E. faecium with vatE was significantly associated with touching raw poultry in the combined hospital patient and vegetarian group ( ). Because none of the P p .032 vegetarian isolates had the vatE gene, we were unable to assess the association between vatE and poultry consumption in the isolates after preexposure to virginiamycin and quinupristin-dalfopristin challenge by the 24-h growth density of untreated isolates and multiplying by 100. b Two and 1 hospital patients who did not use antibiotics in the past month were missing data on touching raw poultry and frequency of poultry consumption, respectively. One vegetarian was missing data on touching raw poultry. c Fisher's exact P for the dichotomous vatE measure. For the continuous inducible resistance (relative percentage of growth) measure, either the Wilcoxon rank-sum test (dichotomous exposure) or the Kruskal-Wallis test (3-category exposure) was used. d Poultry consumption was defined as "high" for those who consumed poultry above the median for the hospital patients (9 times/month), "low" for hospital patients who consumed less, and "veg" for vegetarians.
combined group using statistical methods. However, this association was marginally statistically significant ( ) in P p .058 the hospital patients. Carriage of E. faecium with inducible resistance (higher relative percentage of growth) was significantly associated with touching raw poultry in the hospital patients ( ). Inducible resistance was also significantly P p .027 associated with higher poultry consumption in the combined group of hospital patients and vegetarians ( for both P ! .001 consumption levels in hospital patients vs. vegetarians).
DISCUSSION
The results of the present investigation suggest that virginiamycin use in poultry contributes to human carriage of E. faecium that contains streptogramin resistance genes with readily inducible resistance. A previous study in the United States found that fecal E. faecium with constitutive quinupristin-dalfopristin resistance are rare in humans, but that study did not evaluate the prevalence of streptogramin resistance genes or inducible resistance [19] . In the present study, susceptible and intermediate isolates were screened for both resistance genes and inducible resistance. The acetyltransferase gene vatE was commonly found in both human fecal E. faecium and in isolates colonizing retail poultry. In the risk-factor analysis, touching raw poultry and more frequent poultry consumption were independently associated with the presence of vatE and a phenotype of inducible quinupristin-dalfopristin resistance. In particular, we found striking differences in the characteristics of E. faecium from recently hospitalized patients who ate meat, compared with healthy vegetarians. The vatE gene was not found in any vegetarian E. faecium isolates, but it was found in approximately one-third of isolates from hospital patients. The median level of inducible resistance was also 3-fold higher in persons with a high level of poultry consumption, compared with vegetarians. These positive associations with poultry contact and consumption were found only in persons without recent antibiotic use.
The identification of poultry-related risk factors in the present study is supported by previous studies that have reported a high prevalence of quinupristin-dalfopristin-resistant E. faecium in retail poultry in the United States [16] [17] [18] . Other investigators have also shown that streptogramin-resistant E. faecium occur less frequently in animals raised without antibiotics [20] [21] [22] , and we found that inducible resistance was substantially lower in antibiotic-free retail poultry isolates, relative to those in conventional poultry. The biologic plausibility for the foodborne acquisition of streptogramin resistance genes is further supported by the observation that vatE is located on plasmids and can be transferred by conjugation [16, 35, 36] . In an experimental study, ingestion of streptogramin-resistant E. faecium led to transient colonization for up to 14 days, which provides sufficient time for conjugative transfer of resistance determinants to endogenous flora [37] . In the present study, PFGE failed to identify similar strains in humans and retail poultry, which is consistent with the hypothesis that the horizontal transfer of resistance genes is more important than clonal spread of E. faecium from livestock to humans. The continued nontherapeutic use of virginiamycin and other growth promoters in livestock has been controversial. Virginiamycin use has been banned in Denmark and the European Union, but no regulatory action has been taken by the FDA to prohibit its use in the United States. The FDA has classified streptogramin antibiotics as "highly important" for use in human medicine (available at: http://www.fda.gov/cvm/ guidance/fguide152.pdf), and a risk-assessment model for streptogramin use in food-producing animals has been under development (available at: http://www.fda.gov/cvm/Documents/ SREF_RA_FinalDraft.pdf). However, the lack of critical information about the probability of acquiring streptogramin resistance through the food supply and the potential for human health consequences has made it difficult to develop meaningful risk estimates. The FDA risk assessment assumed that only 10% of quinupristin-dalfopristin-resistant E. faecium infections originated from food pathways. The results of the present study suggest that the FDA model may underestimate the true risk of foodborne acquisition, because streptogramin resistance genes are commonly found in human fecal E. faecium, despite the absence of constitutive streptogramin resistance.
The presence of vatE and inducible streptogramin resistance in the endogenous fecal flora of newly hospitalized patients creates a genetic reservoir for the emergence of streptograminresistant, vancomycin-resistant E. faecium in the hospital environment. E. faecium genogroups have been shown to be associated with different ecologic sources, and isolates carried by healthy people are distinct from those causing nosocomial infection [38, 39] . However, other investigators have suggested that the previous spread of vancomycin-resistant E. faecium infections was due to nosocomial selection of a specific ampicillinresistant E. faecium genotype, with subsequent horizontal transfer of the vanA transposon [39] . We hypothesize that a similar mechanism of spread could occur with streptogramin-resistant E. faecium, although the genetic basis for streptogramin resistance has not been fully elucidated. The selection and horizontal transmission of streptogramin-resistant E. faecium may be clinically unimportant in the present era because of the infrequent use of quinupristin-dalfopristin in hospitals. However, if the use of quinupristin-dalfopristin increases in future years, the presence of vatE and other genes might facilitate the rapid emergence of streptogramin resistance.
There are several caveats with regard to the design and interpretation of the present study. Healthy vegetarians differ from hospitalized patients in many characteristics besides poultry consumption. Although the multivariable analysis adjusted for many of these factors, confounding may have occurred, and other factors associated with vegetarian status may have contributed to the observed associations. In addition, this was a cross-sectional study, and the temporal relationship between poultry exposures and E. faecium characteristics could not be determined. Finally, the food-consumption patterns and other exposures were self-reported, and we could not independently validate the responses. Misclassification of poultry exposures may have occurred, although we expect that any such misclassification would be nondifferential. Additional prospective studies in different populations would be helpful in confirming the major findings. In particular, the relationship between the presence of streptogramin resistance genes and poultry exposure should be assessed in the general population, where recent antibiotic exposure is uncommon. It would also be helpful to conduct a similar study in a country where virginiamycin is not used as a growth promoter.
These findings raise additional concerns regarding the continued use of virginiamycin in food animals. Therapeutic options for serious human vancomycin-resistant enterococcal infections are limited, and quinupristin-dalfopristin is one of few drugs that remain effective. With few new antimicrobials under development, a high priority should be placed on assessing the human health impact of continued streptogramin use in food animals and on developing evidence-based policies to prevent the emergence of streptogramin-resistant infections in hospitals. 
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